查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1575458

脑病变市场：依疾病类型、治疗类型、最终使用者、严重程度、年龄层、诊断方法、应用、病理生理学 - 2025-2030 年全球预测

Encephalopathy Market by Disease Type, Treatment Type, End-User, Severity, Age Group, Diagnosis Method, Application, Pathophysiology - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年脑病变市场价值为1.8534亿美元，预计到2024年将达到1.9685亿美元，复合年增长率为6.15%，预计到2030年将达到2.8153亿美元。

脑病变是指一系列导致大脑功能和结构改变的脑部疾病，通常以精神状态改变、精神错乱和记忆障碍为特征。解决脑病变的需求对患者的生活品质和医疗保健成本产生重大影响，推动了对创新诊断方法、治疗方法和管理解决方案的需求。脑病变主要应用于医疗保健领域，例如医院、神经诊所和復健中心。旨在开发新治疗方法的製药公司和研究机构也使用它。市场成长受到神经系统疾病盛行率上升、老年人口增加、诊断技术进步等因素的显着影响。最近的趋势正在增加个人化医疗的重要性，并为标靶治疗提供了巨大的机会。此外，将人工智慧整合到诊断程序中以及使用生物标记进行早期检测提供了潜在的成长途径。然而，挑战包括高昂的治疗成本、发展中地区缺乏认知以及复杂的法律规范。此外，KEYWORD 的多维性质使诊断和治疗变得复杂，需要强有力的临床研究和跨学科合作。为了利用市场开拓机会，该公司正在开发具有成本效益的便携式诊断设备，投资于标靶治疗的研发，并利用数位健康解决方案来改善治疗的可及性。生物标记研究和远端医疗的创新也可能提供竞争优势。该市场的特点是技术进步迅速，但也面临激烈的竞争和严格的监管。公司应优先考虑策略伙伴关係、併购，以加强其市场地位。透过创新和策略扩张来应对这些挑战，脑病变市场拥有充足的成长空间，为愿意适应和投资尖端研发的公司提供了巨大的潜力。

主要市场统计
基准年[2023] 1.8534 亿美元
预测年份 [2024] 1.9685亿美元
预测年份 [2030] 28153万美元
复合年增长率（%） 6.15%

市场动态：揭示快速发展的脑病变市场的关键市场洞察

供需的动态交互作用正在改变脑病变市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 开发和提供用于准确检测脑病变的专用诊断工具
    • 个人化医疗在调整脑病变患者治疗策略中的作用
    • 糖尿病和高血压等慢性病对脑病变率和治疗的影响
    • 将人工智慧融入神经系统疾病的诊断和进展预测
  • 市场限制因素
    • 治疗和诊断费用高
  • 市场机会
    • 人工智慧在各种脑病变诊断中的整合
    • 全面的病患教育计划，以提高对脑病变治疗的依从性
    • 开发用于远距脑病变患者管理的远端医疗平台
  • 市场挑战
    • 疾病机制与诊断复杂性

波特的五力：驾驭脑病变市场的策略工具

波特的五力框架是了解脑病变市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解脑病变市场的外部影响

外部宏观环境因素在塑造脑病变市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解脑病变市场的竞争状况

对脑病变市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵脑病变市场供应商的绩效评估

FPNV定位矩阵是评估脑病变市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製脑病变市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对脑病变市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 开发和提供用于准确检测脑病变的专用诊断工具
      • 个人化医疗在脑病变患者客製化治疗策略中的作用
      • 糖尿病和高血压等慢性病对脑病变率和治疗的影响
      • 将人工智慧融入神经系统疾病的诊断和进展预测
    • 抑制因素
      • 治疗和诊断费用高
    • 机会
      • 整合人工智慧诊断各种形式的脑病变
      • 全面的病患教育计划，以提高治疗依从性
      • 开发用于远距患者管理的远端医疗平台
    • 任务
      • 疾病机制与诊断复杂性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章脑病变市场：依疾病类型

  • 肝脑病变
  • 高血压脑病变
  • 中毒性代谢性脑病变
  • 创伤脑病变
  • 尿毒症脑病变
  • 韦尼克脑病变

第七章脑病变市场：依治疗类型

  • 药品
    • 抗生素
    • 乳果糖
    • 益生菌
    • Rifaximin
  • 外科手术
    • 肝臟移植
    • 神经外科
  • 治疗方法
    • 行为疗法
    • 认知復健

第八章脑病变市场：依最终用户分类

  • 门诊手术中心
  • 医院
  • 调查机构
  • 专科诊所

第九章脑病变市场：依严重程度

  • 急性脑病变
  • 慢性脑病变
  • 亚急性脑病变

第10章脑病变市场：依年龄组

  • 成人用
  • 老年病
  • 小儿科

第十一章脑病变市场：依诊断方法

  • 验血
  • 脑电图（EEG）
  • 影像
    • 电脑断层扫描
    • MRI
    • 超音波

第十二章脑病变市场：依应用分类

  • 诊断
  • 研究
  • 治疗性的

第十三章脑病变市场：依病理生理学分类

  • 缺氧性脑病变
  • 缺氧缺血性脑病变

第14章北美和南美脑病变市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十五章亚太脑病变市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十六章欧洲、中东和非洲脑病变市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十七章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-535C62918A92

The Encephalopathy Market was valued at USD 185.34 million in 2023, expected to reach USD 196.85 million in 2024, and is projected to grow at a CAGR of 6.15%, to USD 281.53 million by 2030.

Encephalopathy refers to a broad spectrum of brain diseases leading to altered brain function and structure, often characterized by an altered mental state, confusion, and memory problems. The necessity of addressing encephalopathy lies in its significant impact on patients' quality of life and healthcare costs, driving demand for innovative diagnostic approaches, therapeutics, and management solutions. Encephalopathy finds application primarily in healthcare sectors, including hospitals, neurology clinics, and rehabilitation centers. End-use scopes also extend to pharmaceutical companies and research institutes aiming to develop novel treatments. The market's growth is largely influenced by factors such as the rising prevalence of neurological disorders, increasing geriatric population, and advancements in diagnostic technologies. Recent trends include the growing importance of personalized medicine, which opens up significant opportunities for targeted therapies. Moreover, the integration of artificial intelligence in diagnostic procedures and the use of biomarkers for early detection offer avenues for potential growth. However, limitations such as the high cost of treatment, lack of awareness in developing regions, and complex regulatory frameworks pose challenges. Additionally, the multidimensional nature of encephalopathy complicates diagnosis and treatment, necessitating robust clinical research and interdisciplinary collaboration. To capitalize on market opportunities, businesses can focus on developing cost-effective and portable diagnostic devices, investing in research for targeted therapies, and employing digital health solutions to enhance treatment accessibility. Innovations in biomarker research and telemedicine can also provide competitive advantages. The market is characterized by rapid technological advancements but faces intense competition and stringent regulations. Companies should prioritize strategic partnerships, mergers, and acquisitions to bolster their market position. By addressing these challenges through innovation and strategic expansion, there is ample room for growth in the encephalopathy market, offering substantial potential for companies willing to adapt and invest in cutting-edge research and development.

KEY MARKET STATISTICS
Base Year [2023] USD 185.34 million
Estimated Year [2024] USD 196.85 million
Forecast Year [2030] USD 281.53 million
CAGR (%) 6.15%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Encephalopathy Market

The Encephalopathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Development and availability of specialized diagnostic tools for accurate encephalopathy detection
    • The role of personalized medicine in tailoring treatment strategies for encephalopathy patients
    • Impact of chronic diseases such as diabetes and hypertension on encephalopathy prevalence and management
    • Integration of artificial intelligence in diagnosing and predicting the progression of neurological disorders
  • Market Restraints
    • High cost of treatment and diagnostics
  • Market Opportunities
    • Integrating artificial intelligence in diagnosing various forms of encephalopathy
    • Comprehensive patient education programs to improve encephalopathy treatment adherence
    • Developing telemedicine platforms for remote encephalopathy patient management
  • Market Challenges
    • Complexity of disease mechanisms and diagnosis

Porter's Five Forces: A Strategic Tool for Navigating the Encephalopathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Encephalopathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Encephalopathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Encephalopathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Encephalopathy Market

A detailed market share analysis in the Encephalopathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Encephalopathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Encephalopathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Encephalopathy Market

A strategic analysis of the Encephalopathy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Encephalopathy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc, Boehringer Ingelheim International GmbH, Eisai Co., Ltd., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Roche Holdings AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Encephalopathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Hepatic Encephalopathy, Hypertensive Encephalopathy, Toxic-Metabolic Encephalopathy, Traumatic Encephalopathy, Uremic Encephalopathy, and Wernicke's Encephalopathy.
  • Based on Treatment Type, market is studied across Medications, Surgery, and Therapies. The Medications is further studied across Antibiotics, Lactulose, Probiotics, and Rifaximin. The Surgery is further studied across Liver Transplantation and Neurosurgery. The Therapies is further studied across Behavioral Therapy and Cognitive Rehabilitation.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Severity, market is studied across Acute Encephalopathy, Chronic Encephalopathy, and Subacute Encephalopathy.
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Diagnosis Method, market is studied across Blood Tests, Electroencephalogram (EEG), and Imaging. The Imaging is further studied across CT Scan, MRI, and Ultrasound.
  • Based on Application, market is studied across Diagnostic, Research, and Therapeutic.
  • Based on Pathophysiology, market is studied across Anoxic Encephalopathy and Hypoxic Ischemic Encephalopathy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Development and availability of specialized diagnostic tools for accurate encephalopathy detection
      • 5.1.1.2. The role of personalized medicine in tailoring treatment strategies for encephalopathy patients
      • 5.1.1.3. Impact of chronic diseases such as diabetes and hypertension on encephalopathy prevalence and management
      • 5.1.1.4. Integration of artificial intelligence in diagnosing and predicting the progression of neurological disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Integrating artificial intelligence in diagnosing various forms of encephalopathy
      • 5.1.3.2. Comprehensive patient education programs to improve encephalopathy treatment adherence
      • 5.1.3.3. Developing telemedicine platforms for remote encephalopathy patient management
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of disease mechanisms and diagnosis
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Encephalopathy Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Hepatic Encephalopathy
  • 6.3. Hypertensive Encephalopathy
  • 6.4. Toxic-Metabolic Encephalopathy
  • 6.5. Traumatic Encephalopathy
  • 6.6. Uremic Encephalopathy
  • 6.7. Wernicke's Encephalopathy

7. Encephalopathy Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Medications
    • 7.2.1. Antibiotics
    • 7.2.2. Lactulose
    • 7.2.3. Probiotics
    • 7.2.4. Rifaximin
  • 7.3. Surgery
    • 7.3.1. Liver Transplantation
    • 7.3.2. Neurosurgery
  • 7.4. Therapies
    • 7.4.1. Behavioral Therapy
    • 7.4.2. Cognitive Rehabilitation

8. Encephalopathy Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Research Institutes
  • 8.5. Specialty Clinics

9. Encephalopathy Market, by Severity

  • 9.1. Introduction
  • 9.2. Acute Encephalopathy
  • 9.3. Chronic Encephalopathy
  • 9.4. Subacute Encephalopathy

10. Encephalopathy Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. Encephalopathy Market, by Diagnosis Method

  • 11.1. Introduction
  • 11.2. Blood Tests
  • 11.3. Electroencephalogram (EEG)
  • 11.4. Imaging
    • 11.4.1. CT Scan
    • 11.4.2. MRI
    • 11.4.3. Ultrasound

12. Encephalopathy Market, by Application

  • 12.1. Introduction
  • 12.2. Diagnostic
  • 12.3. Research
  • 12.4. Therapeutic

13. Encephalopathy Market, by Pathophysiology

  • 13.1. Introduction
  • 13.2. Anoxic Encephalopathy
  • 13.3. Hypoxic Ischemic Encephalopathy

14. Americas Encephalopathy Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific Encephalopathy Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa Encephalopathy Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2023
  • 17.2. FPNV Positioning Matrix, 2023
  • 17.3. Competitive Scenario Analysis
  • 17.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Biogen Inc
  • 7. Boehringer Ingelheim International GmbH
  • 8. Eisai Co., Ltd.
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis International AG
  • 15. Pfizer Inc.
  • 16. Roche Holdings AG
  • 17. Sanofi S.A.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. ENCEPHALOPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. ENCEPHALOPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENCEPHALOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. ENCEPHALOPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. ENCEPHALOPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENCEPHALOPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENCEPHALOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENCEPHALOPATHY MARKET DYNAMICS
  • TABLE 7. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HYPERTENSIVE ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TOXIC-METABOLIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TRAUMATIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY UREMIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY WERNICKE'S ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LACTULOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RIFAXIMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY NEUROSURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COGNITIVE REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ACUTE ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY CHRONIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SUBACUTE ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ELECTROENCEPHALOGRAM (EEG), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ANOXIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HYPOXIC ISCHEMIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 274. THAILAND ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. THAILAND ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 285. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 286. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 309. DENMARK ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 310. DENMARK ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 311. DENMARK ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 312. DENMARK ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. EGYPT ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 320. EGYPT ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 321. EGYPT ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 322. EGYPT ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 323. EGYPT ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. EGYPT ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 325. FINLAND ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. FINLAND ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. FINLAND ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 328. FINLAND ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 329. FINLAND ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 330. FINLAND ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 331. FINLAND ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 332. FINLAND ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 333. FINLAND ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 334. FINLAND ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 335. FINLAND ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 336. FINLAND ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 337. FRANCE ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. FRANCE ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 339. FRANCE ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 340. FRANCE ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 341. FRANCE ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 342. FRANCE ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 343. FRANCE ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 344. FRANCE ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 345. FRANCE ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 346. FRANCE ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 347. FRANCE ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 348. FRANCE ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 349. GERMANY ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 350. GERMANY ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 351. GERMANY ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 352. GERMANY ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 353. GERMANY ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 354. GERMANY ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 355. GERMANY ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 356. GERMANY ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 357. GERMANY ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 358. GERMANY ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 359. GERMANY ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 360. GERMANY ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 361. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 362. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 363. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 364. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 365. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 366. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 367. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 368. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 369. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 370. ISRAEL ENCEPHALOPATH